Wakelee H - Search Results

1

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Socinski MA, et al. Among authors: wakelee h. J Thorac Oncol. 2018 Feb;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. J Thorac Oncol. 2018. PMID: 29175116 Free article. Review.

2

Docetaxel in advanced non-small cell lung cancer.

Wakelee H, Ramalingam S, Belani CP. Wakelee H, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):13-24. doi: 10.1586/14737140.5.1.13. Expert Rev Anticancer Ther. 2005. PMID: 15757434 Review.

3

Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.

Wakelee HA, Sikic BI. Wakelee HA, et al. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S6-12. doi: 10.3816/clc.2005.s.002. Clin Lung Cancer. 2005. PMID: 16159420 Review.

4

Second- and third-line treatments in non-small cell lung cancer.

Kumar A, Wakelee H. Kumar A, et al. Among authors: wakelee h. Curr Treat Options Oncol. 2006 Jan;7(1):37-49. doi: 10.1007/s11864-006-0030-9. Curr Treat Options Oncol. 2006. PMID: 16343367 Review.

5

Optimizing first-line treatment options for patients with advanced NSCLC.

Wakelee H, Belani CP. Wakelee H, et al. Oncologist. 2005;10 Suppl 3:1-10. doi: 10.1634/theoncologist.10-90003-1. Oncologist. 2005. PMID: 16368866 Free article. Review.

6

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. Le QT, et al. Among authors: wakelee h. Clin Cancer Res. 2006 Mar 1;12(5):1507-14. doi: 10.1158/1078-0432.CCR-05-2049. Clin Cancer Res. 2006. PMID: 16533775 Free article.

7

Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.

Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Wakelee HA, et al. Cancer. 2006 May 15;106(10):2208-17. doi: 10.1002/cncr.21869. Cancer. 2006. PMID: 16604529 Free article.

8

Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.

Wakelee HA, Schiller JH, Gandara DR. Wakelee HA, et al. Clin Lung Cancer. 2006 Jul;8(1):18-21. doi: 10.3816/CLC.2006.n.028. Clin Lung Cancer. 2006. PMID: 16870041 Review.

9

A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma.

Roy MS, Le QT, Donington JS, Wakelee HA. Roy MS, et al. Clin Lung Cancer. 2006 Sep;8(2):146-8. doi: 10.3816/CLC.2006.n.044. Clin Lung Cancer. 2006. PMID: 17026817

10

Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.

Wakelee H, Dubey S, Gandara D. Wakelee H, et al. Oncologist. 2007 Mar;12(3):331-7. doi: 10.1634/theoncologist.12-3-331. Oncologist. 2007. PMID: 17405898 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

342 results

Search Page